title: Effects of interleukin-2 immunotherapy on soluble lymphocyte markers in cancer patients.
authors.forename: P
authors.initials: P
authors.lastname: Lissoni
authors.forename: F
authors.initials: F
authors.lastname: Rovelli
authors.forename: E
authors.initials: E
authors.lastname: Tisi
authors.forename: D
authors.initials: D
authors.lastname: Ballabio
authors.forename: C
authors.initials: C
authors.lastname: Benenti
authors.forename: A
authors.initials: A
authors.lastname: Ardizzoia
authors.forename: S
authors.initials: S
authors.lastname: Barni
authors.forename: B
authors.initials: B
authors.lastname: Tancini
mesh_terms: D000328:Adult; D000945:Antigens, Differentiation, T-Lymphocyte / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D015704:CD4 Antigens / Q000097:blood; D016827:CD8 Antigens / Q000097:blood; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000276:immunology / Q000628:therapy*; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000097:blood / Q000276:immunology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015375:Receptors, Interleukin-2 / Q000378:metabolism; D012995:Solubility
chemical_list: D000945:Antigens, Differentiation, T-Lymphocyte; D015415:Biomarkers; D015704:CD4 Antigens; D016827:CD8 Antigens; D007376:Interleukin-2; D015375:Receptors, Interleukin-2